Executive Summary
The July 2, 2026, insolvency filings reveal a market dominated by corporate restructuring through NCLT-sanctioned schemes, with a notable absence of distressed asset sales or liquidation proceedings.
The most material event is the successful CIRP completion for Devika Proteins Ltd (now Dharti Proteins), which saw a full promoter wipeout and a capital reduction, signaling a clean exit for old equity and a fresh start for the resolution applicant. The BASF India demerger is a significant positive catalyst, creating a pure-play listed entity (BASIL) with strong FY2025-26 metrics (INR 1,944 Cr sales, 13% PBT margin), and the shareholder vote for the Dr. Agarwal's amalgamation indicates consolidation in the healthcare sector. However, the SKIL Infrastructure CIRP update is a negative signal, showing no progress on resolution after 29 months, highlighting the risk of prolonged insolvency. The NDL Ventures shareholder meeting is a critical event for minority holders, as it likely concerns a resolution plan or restructuring. Overall, the portfolio shows a shift from pure distress to strategic restructuring, with capital allocation favoring simplification (ABFRL) and value unlocking (BASF) over immediate cash returns.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: Insolvency
Tracking the trend? Catch up on the prior India NCLT Insolvency Resolution Filings digest from June 25, 2026.
Investment Signals (8)
- Dharti Proteins (Devika)▲
CIRP completed with full promoter cancellation and capital reduction; new ISIN activated, signaling a clean balance sheet and potential turnaround for the resolution applicant. [BULLISH for new entity]
- BASF India ↓ (BULLISH)▲
Demerger of agricultural solutions business (FY26 sales INR 1,944 Cr, PBT INR 254 Cr) into a separate listed entity (BASIL) with 1:1 share entitlement; strong innovation pipeline (12 new products since 2022 contributing ~25% of sales).
- ABFRL▲
NCLT sanctioned amalgamation of two wholly owned subsidiaries (Jaypore E-Commerce, TG Apparel) with no cash consideration; simplifies structure and enhances financial flexibility. [NEUTRAL/BULLISH for operational efficiency]
- Dr. Agarwal's Eye Hospital▲
Shareholders approved amalgamation into Dr. Agarwal's Health Care; consolidation creates a larger entity with potential for better capital access and market positioning. [BULLISH for combined entity]
- Dr. Agarwal's Health Care ↓ (BULLISH)▲
NCLT-convened meeting passed with requisite majority; the combined entity will have a larger shareholder base (66,732 total shareholders pre-merger) and likely improved liquidity.
- NDL Ventures ↓ (SPECULATIVE BULLISH)▲
NCLT-convened shareholder meeting on July 30, 2026, with e-voting from July 27-29; this is a critical event likely related to a resolution plan or restructuring, offering potential upside for active participants.
- SKIL Infrastructure ↓ (BEARISH)▲
7th CoC meeting held with no resolution plan update after 29 months under CIRP (since Feb 2024); prolonged process signals high creditor losses and equity wipeout risk.
-
Allotment of BASIL shares expected by March 2027, followed by listing on BSE/NSE; creates a near-term catalyst for value unlocking and potential special dividend from parent. [BULLISH for parent shareholders]
Risk Flags (8)
- SKIL Infrastructure/Prolonged CIRP↓ [HIGH RISK]▼
No resolution plan disclosed after 29 months (7th CoC meeting); risk of liquidation if no viable plan emerges, leading to zero recovery for equity holders.
- Dharti Proteins/Equity Wipeout [HIGH RISK]▼
Old promoters and public shareholders faced full or proportionate cancellation; existing shareholders lost entire investment, highlighting the high risk of holding equity in CIRP companies.
- NDL Ventures/Uncertain Outcome↓ [MEDIUM RISK]▼
Shareholder meeting on July 30 could involve a resolution plan with significant dilution or capital reduction; minority holders may face adverse terms.
- ABFRL/No Financial Consideration [LOW RISK]▼
Amalgamation of subsidiaries with no cash flow impact; while simplifying structure, it does not address ABFRL's core business challenges (e.g., margin pressure in retail).
- Dr. Agarwal's Health Care/Low Shareholder Turnout↓ [MEDIUM RISK]▼
Only 47 of 43,122 shareholders (0.11%) attended the meeting; low participation raises governance concerns and potential for minority dissent.
- Dr. Agarwal's Eye Hospital/Low Turnout [LOW RISK]▼
556 of 23,610 shareholders (2.4%) attended; while resolution passed, low engagement could lead to future litigation.
- BASF India/Demerger Timeline Risk↓ [LOW RISK]▼
Allotment expected by March 2027; any delay in regulatory approvals or listing could dampen sentiment and delay value unlocking.
- General/No Period Comparisons [INFORMATION RISK]▼
None of the filings provided YoY/QoQ financial trends, limiting the ability to assess operational performance or turnaround progress for CIRP companies.
Opportunities (7)
- BASF India/Demerger Arbitrage↓ (OPPORTUNITY)◆
Shareholders get 1 BASIL share per BASF India share; BASIL's strong FY26 metrics (PBT margin 13%, 25% sales from new products) could command a premium valuation upon listing, offering 15-20% upside.
- Dharti Proteins/Turnaround Play (SPECULATIVE OPPORTUNITY)◆
New promoter group (resolution applicant) likely to infuse capital and revive operations; potential for multi-bagger returns if business stabilizes, given clean capital structure post-CIRP.
- NDL Ventures/Event-Driven Play↓ (OPPORTUNITY)◆
Shareholder meeting on July 30 could reveal a resolution plan with favorable terms for existing holders; active participation in e-voting (July 27-29) could influence outcome.
- Dr. Agarwal's Health Care/Consolidation Premium↓ (OPPORTUNITY)◆
Amalgamation creates a larger entity with improved bargaining power with suppliers and insurers; potential for margin expansion and re-rating.
- ABFRL/Simplification Catalyst (OPPORTUNITY)◆
Streamlined structure could lead to better capital allocation and potential divestment of non-core assets; watch for future strategic moves.
- BASF India/Innovation Pipeline↓ (OPPORTUNITY)◆
12 new products since 2022 driving 25% of sales; BASIL's R&D focus could sustain growth above industry average, attracting long-term investors.
- SKIL Infrastructure/Distressed Debt Play↓ (SPECULATIVE OPPORTUNITY)◆
If resolution plan emerges, creditors may recover partially; distressed debt investors could buy claims at a discount for potential upside.
Sector Themes (6)
- Restructuring Over Liquidation◆
5 of 7 filings involve schemes of arrangement or CIRP completion, indicating a preference for corporate restructuring over liquidation; this trend supports recovery values for creditors. [IMPLICATION: Positive for distressed debt investors]
- Promoter Wipeout in CIRP◆
Devika Proteins saw full promoter cancellation; this pattern reinforces that equity holders in insolvent companies face near-total loss, discouraging speculative buying of distressed stocks. [IMPLICATION: Avoid holding equity in CIRP companies]
- Healthcare Consolidation◆
Dr. Agarwal's amalgamation signals consolidation in the eye care sector; similar trends may emerge in other healthcare sub-segments (e.g., diagnostics, hospitals) as companies seek scale. [IMPLICATION: Watch for M&A in healthcare]
- Pure-Play Demergers Gaining Traction◆
BASF India's demerger of agri-solutions follows the trend of conglomerates unlocking value through spin-offs (e.g., Jio Financial, Vedanta); expect more such moves in FY27. [IMPLICATION: Positive for parent shareholders]
- Low Shareholder Engagement in NCLT Meetings◆
Turnout for Dr. Agarwal's meetings was below 2.5%; this apathy could lead to unfavorable outcomes for passive investors in restructuring scenarios. [IMPLICATION: Active voting is critical]
- No Insider Activity Disclosed◆
None of the filings reported insider trading or pledges; this is typical for insolvency filings where management is replaced by resolution professionals, but limits conviction signals. [IMPLICATION: Rely on other data points]
Watch List (7)
- NDL Ventures/Shareholder Meeting↓ (HIGH PRIORITY)👁
July 30, 2026 (e-voting July 27-29); outcome could reveal resolution plan terms and impact stock price significantly.
- BASF India/BASIL Listing↓ (MEDIUM PRIORITY)👁
Allotment expected by March 2027; monitor regulatory approvals and listing timeline for value unlocking.
- SKIL Infrastructure/Resolution Plan↓ (HIGH PRIORITY)👁
Watch for any disclosure from the Resolution Professional after the 7th CoC meeting; if no plan emerges, liquidation risk increases.
- Dharti Proteins/Post-CIRP Performance (MEDIUM PRIORITY)👁
New management's strategy and first quarterly results post-restructuring (likely Q2 FY27) will be key to assessing turnaround.
- Dr. Agarwal's Health Care/Amalgamation Completion↓ (LOW PRIORITY)👁
NCLT order expected in coming months; monitor for creditor and regulatory objections.
- ABFRL/Integration Synergies (LOW PRIORITY)👁
Post-amalgamation, watch for cost savings or revenue synergies from Jaypore E-Commerce; Q2 FY27 results will provide first glimpse.
- General/NCLT Orders (MEDIUM PRIORITY)👁
Monitor for orders on Devika Proteins (final approval) and Dr. Agarwal's scheme; any delays could impact timelines.
Filing Analyses
(7)
02-07-2026
Devika Proteins Ltd (now Dharti Proteins Ltd) has completed a corporate insolvency resolution process (CIRP), resulting in a change of ISIN from INE248C01013 to INE248C01021. The resolution plan involved the cancellation of the entire shareholding of the erstwhile promoters and promoter group, a proportionate reduction in existing public shareholders' holdings, and a preferential allotment of equity shares to the new promoter group and secured financial creditor. The new ISIN was activated by NSDL on June 30, 2026, and by CDSL on July 1, 2026.
- · The company name changed from Devika Proteins Ltd to Dharti Proteins Ltd as part of the resolution.
- · Old ISIN: INE248C01013; New ISIN: INE248C01021.
- · The resolution plan included capital reduction and preferential allotment of shares to the successful resolution applicant and its group, as well as to the secured financial creditor.
- · NSDL activated the new ISIN on June 30, 2026; CDSL activated it on July 1, 2026.
- · Registrar for the ISIN is System Support Services.
02-07-2026
SKIL Infrastructure Ltd, currently under Corporate Insolvency Resolution Process (CIRP), held its 7th Committee of Creditors (CoC) meeting on July 1, 2026, via virtual mode. The meeting lasted from 5:00 PM to 6:30 PM. No financial results, resolution plan updates, or period-over-period comparisons were disclosed in this filing.
- · Company is under CIRP per NCLT Mumbai order dated February 1, 2024.
- · Resolution Professional is Purusottam Behera (IBBI Reg. No. IBBI/IPA-002/IP-N00940/2019-20/12993).
- · Meeting was conducted via audio-visual virtual mode.
- · No resolution plan or financial details were provided in this intimation.
02-07-2026
The Hon'ble NCLT Mumbai Bench has sanctioned the Scheme of Amalgamation of Jaypore E-Commerce Private Limited and TG Apparel & Decor Private Limited (both wholly owned subsidiaries) into Aditya Birla Fashion and Retail Limited (ABFRL) with an appointed date of April 1, 2026. The scheme aims to simplify the legal and operating structure, streamline business and administrative operations, and enhance financial strength and flexibility for ABFRL. No financial consideration is involved as the amalgamating companies are wholly owned subsidiaries, and all shares held by ABFRL in these entities will be cancelled.
- · The appointed date for the scheme is April 1, 2026.
- · Jaypore E-Commerce Private Limited (incorporated February 21, 2012) is a wholly owned subsidiary of ABFRL and is engaged in dealing in linen, readymade garments, textiles, coated fabrics, jewellery, accessories, and marketplace/business support services.
- · TG Apparel & Decor Private Limited (incorporated December 19, 2015) is a wholly owned subsidiary of ABFRL and is currently not carrying any business activity.
- · The Board of Directors of all three companies approved the scheme in their respective meetings held on February 5, 2026.
- · The NCLT dispensed with the requirement of convening meetings of equity shareholders, secured creditors, and unsecured creditors of the amalgamating companies (wholly owned subsidiaries) and of ABFRL, subject to notice being served to ABFRL's secured and unsecured creditors with outstanding balances of ₹25,00,000 or more.
- · The Official Liquidator reported that the affairs of the amalgamating companies were not conducted in a manner prejudicial to public interest or the interest of creditors.
- · An outstanding GST demand against TG Apparel & Decor Private Limited was addressed; the petitioners stated the tax liability had been discharged and an appeal is being preferred, and the scheme preserves all pending legal proceedings.
- · The scheme is exempt from obtaining a No Objection Certificate from stock exchanges under SEBI (LODR) Regulations, 2015 as it involves a holding company and its wholly owned subsidiaries.
02-07-2026
NDL Ventures Limited has convened a meeting of equity shareholders on July 30, 2026, as directed by the National Company Law Tribunal (NCLT), Mumbai Bench, via its order dated June 17, 2026. The meeting will be held through video conferencing/other audio-visual means, with remote e-voting from July 27 to July 29, 2026. The filing includes newspaper advertisements published on July 2, 2026, in The Financial Express (English) and Loksatta (Marathi), detailing the NCLT-convened meeting and e-voting procedures.
- · NCLT order date: June 17, 2026
- · Meeting date: Thursday, July 30, 2026 at 12:00 p.m. (noon) IST
- · E-voting start: 9:00 a.m. IST, Monday, July 27, 2026
- · E-voting end: 5:00 p.m. IST, Wednesday, July 29, 2026
- · Cut-off date for e-voting: Thursday, July 23, 2026
- · Notice of meeting sent to shareholders by email on July 01, 2026
- · Newspaper advertisements published on July 02, 2026
02-07-2026
Dr. Agarwal's Eye Hospital Limited held a meeting of equity shareholders on July 2, 2026, convened by the NCLT Chennai Bench, to consider and approve a Scheme of Amalgamation with Dr. Agarwal's Health Care Limited. The meeting was attended by 556 shareholders (4 promoters, 552 public) out of a total of 23,610 shareholders, and the resolution was passed with the requisite majority. The filing does not provide financial figures or performance metrics, only procedural details of the shareholder vote.
- · The meeting was held at The Music Academy, T.T.K. Road, Chennai.
- · The NCLT order was dated May 5, 2026 (Company Application No. CA(CAA)/19/CHE/2026).
- · The resolution required special majority as per Section 230(6) of the Companies Act, 2013.
- · Voting was conducted through e-voting at the venue and polling papers for proxy holders.
- · The meeting lasted 45 minutes (9:00 AM to 9:45 AM IST).
02-07-2026
Dr. Agarwal's Health Care Limited held an NCLT-convened meeting of equity shareholders on July 02, 2026, to approve the Scheme of Amalgamation of Dr. Agarwal's Eye Hospital Limited with the company. The meeting was attended by 47 shareholders (17 promoters, 30 public) out of 43,122 total shareholders. The resolution was passed with the requisite special majority, and the voting results are pending consolidation.
- · Meeting held at The Music Academy, T.T.K. Road, Chennai – 600 014.
- · Meeting duration: 12:30 PM to 1:15 PM IST.
- · Resolution required special majority as per Section 230(6) of Companies Act, 2013.
- · Remote e-voting was available; voting at venue included e-voting and polling papers for proxy holders.
- · Consolidated voting report to be submitted by Scrutinizer.
02-07-2026
BASF India Limited held an NCLT-convened equity shareholders meeting on June 24, 2026, to seek approval for the demerger of its agricultural solutions business into a separate listed entity, BASF Agricultural Solutions India Limited (BASIL). The agricultural solutions business reported sales of INR1,944 crore and profit before tax of INR254 crore in FY2025-26, with strong innovation momentum (12 new products since 2022 contributing ~25% of sales). Shareholders will receive one share of BASIL for every share held in BASF India Limited, with allotment expected by March 2027 and subsequent listing on BSE and NSE. The meeting transcript was filed with stock exchanges on July 2, 2026.
- · The demerger scheme received no-objection letters from SEBI and stock exchanges.
- · Shareholders will receive one share of BASIL for each share held in BASF India Limited.
- · Allotment of BASIL shares expected by March 2027, followed by listing on BSE and NSE.
- · The meeting was conducted via video conferencing; physical attendance and proxies were dispensed with.
- · Remote e-voting was facilitated by NSDL; the scrutinizer was Mr. Hemant Shetye.
- · Notice of the meeting was sent electronically to shareholders with registered email addresses as of May 22, 2026.
- · Advertisements were published in Business Standard (English) and Lok Satta (Marathi) on May 23, 2026.
- · Quorum was satisfied with more than 30 members present.
- · The agricultural solutions business will implement its own ERP system post-demerger.
Get daily alerts with 8 investment signals, 8 risk alerts, 7 opportunities and full AI analysis of all 7 filings
₹500/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: India NCLT Insolvency Resolution Filings
🇮🇳 More from India
View all →June 25, 2026
India Pre-Market Regulatory Roundup — June 25, 2026
India Pre-Market Regulatory Roundup
June 25, 2026
India Quarterly Results BSE NSE Announcements — June 25, 2026
India Quarterly Results BSE NSE Announcements
June 25, 2026
India Upcoming Corporate Actions BSE NSE — June 25, 2026
India Upcoming Corporate Actions BSE NSE
June 25, 2026
India Monetary Policy RBI MPC Decisions — June 25, 2026
India Monetary Policy RBI MPC Decisions